您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
回爱民
回爱民
所属职位: 执行总裁,全球研发总裁,兼CMO
所属公司:

复星医药

回爱民博士,复星医药执行总裁,全球研发总裁,首席医学官。现兼任上海市干细胞治疗重点实验室主任,中国药促会肿瘤学委员会副主任。曾担任赛诺菲全球临床研发副总裁, 第五届中国肿瘤学术大会学术委员会副主任。亲自领导了IzaxomibIsatuximab等多个小分子及生物制剂抗癌药的全球研发,注册,上市。主导了伊莎咗咪,阿伐曲珀帕等多款创新药在中国的研发注册上市。在新英格兰医学杂志,自然医学,柳叶刀,细胞癌症等发表论文八十余篇。最近主导了复星医药与BioNTech合作mRNA新冠疫苗项目协约签署及大中华区域研发,注册(港澳已上市)。

 

Dr. Aimin Hui is the Executive President of Fosun Pharma, President of Global R&D, and Chief Medical Officer. He is currently the Director of Shanghai Key Laboratory of Stem Cell Therapy and the Deputy Director of the Oncology Committee of China Pharmaceutical Association. He was the Vice President of Global Clinical R&D of Sanofi and the Vice Chairman of the Academic Committee of the 5th China Academic Oncology Conference. He has led the global development, registration and marketing of several small molecule and biologic anti-cancer drugs such as Izaxomib and Isatuximab. He has led the development and registration of several innovative drugs such as Ixazomib and Avatrombopag in China. He has published more than 80 papers in New England Journal of Medicine, Nature Medicine, Lancet, Cell Cancer, etc. Recently, he led the collaboration between Fosun and BioNTech on the development and registration of mRNA vaccines in Greater China (already marketed in Hong Kong and Macau).



微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务